CD274 and non-small cell lung carcinoma: Immunocheckpoint inhibitors (ICIs) targeting programmed cell death‐1 (PD‐1) or programmed cell death‐ligand 1 (PD‐L1) have been widely adopted in patients with NSCLC.2, 3, 4, 5, 6, 7, 8, 9, 10, 11